TLPH
Talphera's Q2 2026 Results: A Leap Forward in CRRT Anticoagulation
Talphera, a leading player in the medical field, has announced its second quarter 2026 financial results, and with it, significant progress in their registrational trial for nafamostat as an anticoagulant for continuous renal replacement therapy (CRRT). The company's Chief Executive Officer, Vince Angotti, highlighted this achievement during the